**Appendix Table D145. Adverse effects with beta-blockers for migraine prevention in adults (results from randomized controlled clinical trials)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Active Drug** | **Outcome, Reference** | **Sample** | **Rate with Drug****[Placebo]** | **Odds Ratio****(95% CI)** | **Absolute Risk Difference****(95% CI)** | **Number Needed to Treat to Harm****(95% CI)** | **Attributable Events per 1000 Treated****(95% CI)** |
| Atenolol | Tiredness, diffuse62, 95 | 118 | 5.1 [0.0] | 4.2 (0.4 to 38.8) | 0.04 (-0.02 to 0.11) | NS | NS |
| **Metoprolol**  | **Fatigue97, 102** | **91** | **18.2 [4.3]** | **4.6 (0.9 to 24.4)** | **0.14 (0.02 to 0.27)** | **7 (4 to 67)** | **141 (15 to 268)** |
| **Metoprolol**  | **Sleep disturbances97, 100** | **225** | **9.9 [4.4]** | **2.3 (0.6 to 9.1)** | **0.05 (0.00 to 0.11)** | **19 (9 to 1000)** | **54 (1 to 106)** |
| Metoprolol  | Gastrointestinal disturbances97, 102 | 91 | 2.3 [12.8] | 0.2 (0.0 to 1.3) | -0.10 (-0.20 to 0.01) | NS | NS |

Bold = significant differences at 95% CI when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0; NS= not significant; Number needed to treat and number of attributable events were calculated for statistically significant differences